2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation

Updated: August 17, 2026

More than 10.5 million American adults, comprising more than 4.5% of the adult US population, currently carry a diagnosis of AF. The lifetime risk of AF is estimated to be 1 in 3. AF is associated with higher health care utilization and costs. To increase the clinical dissemination of the most recent atrial fibrillation clinical practice guidelines and to enhance the implementation of the evidence-based recommendations, the ACC/AHA Joint Committee on Performance Measures convened a writing committee to develop performance and quality measures for atrial fibrillation.
The new and updated measures presented in the “2026 AHA/ACC Clinical Performance and Quality Measures for Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures” are based on the strongest recommendations (Class 1 or Class 3) from the “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation.”
The AHA/ACC Atrial Fibrillation Measure Set can be used to assess, measure, and compare care processes for patients with atrial fibrillation across multiple providers and institutions.

Supporting Materials